PROSTATE-SPECIFIC ANTIGEN IN SCREENING OF PROSTATE-CANCER

被引:15
作者
CHU, TM
机构
[1] Department of Diagnostic Immunology Research and Biochemistry, Roswell Park Cancer Institute, New York State Department of Health, Buffalo, New York
关键词
EARLY DETECTION; DIGITAL RECTAL EXAMINATION; TRANSRECTAL ULTRASONOGRAPHY; LOCALIZED CANCERS;
D O I
10.1002/jcla.1860080511
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Prostate-specific antigen (PSA) is a well-characterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurrent disease. The greatest clinical value of PSA is as an aid for early detection of prostate cancer. Recent studies have indicated that PSA-based screening of the older population for organ-confined early-stage prostate cancer is an acceptable, practical, and reliable modality. The accuracy of PSA screening is within the same range as the mammogram. The cost-effectiveness of PSA is comparable to other cancer screening tests. Although the increase in the patient's survival due to PSA-based detection of early prostate cancer remains to be documented, it is generally agreed that the PSA test along with digital rectal examination (DRE) should be included in the annual physical examination for men 50 years of age or older. High-risk men are urged to commence at age 40. Asymptomatic men who have both a negative DRE and normal PSA blood test need only to continue an annual DRE and PSA check-up. Men who have a negative DRE and elevated PSA, and all those who have a suspicious DRE regardless of PSA results, should undergo further diagnostic workup, such as transrectal ultrasonography with biopsy of visible lesions. The cure rate is high with timely treatment, when prostate cancer is detected while still confined to the prostate. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:323 / 326
页数:4
相关论文
共 45 条
  • [1] SERUM PROSTATE-SPECIFIC ANTIGEN - THE MOST USEFUL TUMOR-MARKER
    ANDRIOLE, GL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) : 1205 - 1207
  • [2] BAN Y, 1984, BIOCHEM BIOPH RES CO, V123, P482, DOI 10.1016/0006-291X(84)90256-0
  • [3] SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN
    BRAWER, MK
    CHETNER, MP
    BEATIE, J
    BUCHNER, DM
    VESSELLA, RL
    LANGE, PH
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 841 - 845
  • [4] BRAWER MR, 1989, UROLOGY, V33, pS11
  • [5] CARTER HB, 1992, CANCER RES, V52, P3323
  • [6] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [7] DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    BASLER, JW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08): : 948 - 954
  • [8] RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER
    CHODAK, GW
    THISTED, RA
    GERBER, GS
    JOHANSSON, JE
    ADOLFSSON, J
    JONES, GW
    CHISHOLM, GD
    MOSKOVITZ, B
    LIVNE, PM
    WARNER, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) : 242 - 248
  • [9] CHU TM, 1986, UROLOGY, V27, P487
  • [10] PROSTATE-SPECIFIC ANTIGENIC DOMAIN OF HUMAN-PROSTATE SPECIFIC ANTIGEN IDENTIFIED WITH MONOCLONAL-ANTIBODIES
    CHU, TM
    KAWINSKI, E
    HIBI, N
    CROGHAN, G
    WILEY, J
    KILLIAN, CS
    CORRAL, D
    [J]. JOURNAL OF UROLOGY, 1989, 141 (01) : 152 - 156